According to the cBioPortal database, 6 to 21% of ovarian serous cystadenocarcinomas, lung squamous cell and adenocarcinomas, uterine endometriod carcinomas, stomach adenocarcinomas, adrenocortical carcinomas, esophageal carcinomas, bladder urothelial carcinomas and pancreatic adenocarcinomas contained an amplification of a MEF2 gene, whereas instead of but 0 to 2.6% of these cancers contained a MEF2 gene deletion [131, 132, 138–140] (Figure 2A). This evidence concerns the gene MEF2A and pancreatic adenocarcinoma.